Pomanda estimates the enterprise value of WOODEND PHARMA LTD at £550.2k based on a Turnover of £1.2m and 0.47x industry multiple (adjusted for size and gross margin).
woodend pharma ltdEstimated Valuation
£730.7k
Pomanda estimates the enterprise value of WOODEND PHARMA LTD at £730.7k based on an EBITDA of £188.8k and a 3.87x industry multiple (adjusted for size and gross margin).
woodend pharma ltdEstimated Valuation
£80.6k
Pomanda estimates the enterprise value of WOODEND PHARMA LTD at £80.6k based on Net Assets of £38.8k and 2.08x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Woodend Pharma LtdOverview
Woodend Pharma Ltd is a live company located in coventry, CV2 2EU with a Companies House number of 12265125. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in October 2019, it's largest shareholder is
gulam jaffer nabi
with a 33.3% stake. Woodend Pharma Ltd is a young,
small sized company, Pomanda has estimated its turnover at
£1.2m with
declining
growth in recent years.
Pomanda's financial health check has awarded Woodend Pharma Ltd a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 5 areas for improvement. Company Health Check FAQs
Health Rating3.5out of 5
4 Strong
2 Regular
5 Weak
Size
annual sales of £1.2m, make it smaller than the average company (£12.6m)
£1.2m - Woodend Pharma Ltd
£12.6m - Industry AVG
Growth
3 year (CAGR) sales growth of -4%, show it is growing at a slower rate (6.3%)
-4% - Woodend Pharma Ltd
6.3% - Industry AVG
Production
with a gross margin of 40.5%, this company has a comparable cost of product (40.5%)
40.5% - Woodend Pharma Ltd
40.5% - Industry AVG
Profitability
an operating margin of 10.4% make it more profitable than the average company (8%)
10.4% - Woodend Pharma Ltd
8% - Industry AVG
Employees
with 8 employees, this is below the industry average (24)
8 - Woodend Pharma Ltd
24 - Industry AVG
Pay Structure
on an average salary of £57.5k, the company has an equivalent pay structure (£57.5k)
£57.5k - Woodend Pharma Ltd
£57.5k - Industry AVG
Efficiency
resulting in sales per employee of £146.2k, this is less efficient (£369.3k)
£146.2k - Woodend Pharma Ltd
£369.3k - Industry AVG
Debtor Days
it gets paid by customers after 31 days, this is earlier than average (46 days)
31 days - Woodend Pharma Ltd
46 days - Industry AVG
Creditor Days
its suppliers are paid after 83 days, this is slower than average (31 days)
83 days - Woodend Pharma Ltd
31 days - Industry AVG
Stock Days
it holds stock equivalent to 13 days, this is less than average (38 days)
13 days - Woodend Pharma Ltd
38 days - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Woodend Pharma Ltd
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 96.7%, this is a higher level of debt than the average (45.4%)
96.7% - Woodend Pharma Ltd
45.4% - Industry AVG
WOODEND PHARMA LTD financials
EXPORT
Woodend Pharma Ltd's latest turnover from December 2023 is estimated at £1.2 million and the company has net assets of £38.8 thousand. According to their latest financial statements, Woodend Pharma Ltd has 8 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Turnover
1,169,496
1,135,338
1,110,792
1,309,680
Other Income Or Grants
Cost Of Sales
695,480
656,832
646,737
776,272
Gross Profit
474,016
478,505
464,056
533,409
Admin Expenses
352,572
326,910
469,062
498,010
Operating Profit
121,444
151,595
-5,006
35,399
Interest Payable
106,229
99,951
45,248
10,814
Interest Receivable
8,525
10,618
758
162
Pre-Tax Profit
23,740
62,262
-49,496
24,747
Tax
-5,935
-11,830
-4,702
Profit After Tax
17,805
50,432
-49,496
20,045
Dividends Paid
Retained Profit
17,805
50,432
-49,496
20,045
Employee Costs
460,383
431,947
408,402
382,996
Number Of Employees
8
8
8
8
EBITDA*
188,813
218,964
62,363
102,768
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Tangible Assets
4,000
9,750
15,500
21,250
Intangible Assets
701,516
763,135
824,754
886,373
Investments & Other
Debtors (Due After 1 year)
302,851
Total Fixed Assets
1,008,367
772,885
840,254
907,623
Stock & work in progress
25,000
39,000
39,000
39,000
Trade Debtors
101,646
100,017
97,330
192,540
Group Debtors
Misc Debtors
26,278
24,408
24,424
13,588
Cash
324,750
281,983
324,666
misc current assets
total current assets
152,924
488,175
442,737
569,794
total assets
1,161,291
1,261,060
1,282,991
1,477,417
Bank overdraft
488,661
74,115
74,115
Bank loan
Trade Creditors
159,524
154,025
159,244
114,415
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
85,321
75,199
59,822
988,387
total current liabilities
733,506
303,339
293,181
1,102,802
loans
388,996
936,737
1,019,258
354,567
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
388,996
936,737
1,019,258
354,567
total liabilities
1,122,502
1,240,076
1,312,439
1,457,369
net assets
38,789
20,984
-29,448
20,048
total shareholders funds
38,789
20,984
-29,448
20,048
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Operating Activities
Operating Profit
121,444
151,595
-5,006
35,399
Depreciation
5,750
5,750
5,750
5,750
Amortisation
61,619
61,619
61,619
61,619
Tax
-5,935
-11,830
-4,702
Stock
-14,000
39,000
Debtors
306,350
2,671
-84,374
206,128
Creditors
5,499
-5,219
44,829
114,415
Accruals and Deferred Income
10,122
15,377
-928,565
988,387
Deferred Taxes & Provisions
Cash flow from operations
-93,851
214,621
-736,999
955,740
Investing Activities
capital expenditure
-974,992
Change in Investments
cash flow from investments
-974,992
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
-547,741
-82,521
664,691
354,567
Hire Purchase and Lease Commitments
other long term liabilities
share issue
3
interest
-97,704
-89,333
-44,490
-10,652
cash flow from financing
-645,445
-171,854
620,201
343,918
cash and cash equivalents
cash
-324,750
42,767
-42,683
324,666
overdraft
414,546
74,115
change in cash
-739,296
42,767
-116,798
324,666
woodend pharma ltd Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for woodend pharma ltd. Get real-time insights into woodend pharma ltd's credit score, group structure and payment trends.
Perform a competitor analysis for woodend pharma ltd by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other small companies, companies in CV2 area or any other competitors across 12 key performance metrics.
woodend pharma ltd Ownership
WOODEND PHARMA LTD group structure
Woodend Pharma Ltd has no subsidiary companies.
Ultimate parent company
WOODEND PHARMA LTD
12265125
WOODEND PHARMA LTD Shareholders
The largest shareholders in Woodend Pharma Ltd include Gulam Jaffer Nabi and Danish Vitran.
gulam jaffer nabi
33.33%
danish vitran
33.33%
jasjeev singh rai
33.33%
woodend pharma ltd directors
Woodend Pharma Ltd currently has 3 directors.
The longest serving directors include
Mr Gulam Nabi (Oct 2019) and
Mr Danish Vitran (Oct 2019).
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 3 charges/mortgages relating to woodend pharma ltd. Currently there are 3 open charges and 0 have been satisfied in the past.
woodend pharma ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for WOODEND PHARMA LTD. This can take several minutes, an email will notify you when this has completed.
woodend pharma ltdCompanies House Filings - See Documents
